# Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

> **NCT02778386** · PHASE1 · UNKNOWN · sponsor: **N&N Pharmaceuticals Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Toxicity

## Interventions

- **DRUG:** N-Methanocarbathymidine
- **OTHER:** Placebo Capsule

## Key facts

- **NCT ID:** NCT02778386
- **Lead sponsor:** N&N Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2016-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778386, "Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02778386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*